Cardiac Safety After Thoracic Radiotherapy in Adults
Official title: Cardiac Safety Management and Immune Microenvironment Changes in Thoracic Cancer Patients Receiving Different Radiotherapy Modalities: A Prospective Observational Study
Run by Hebei Medical University Fourth Hospital · NCT07669493 · Data updated 2026-11-12
We’re testing how well cardiac safety checks after thoracic radiotherapy can spot early heart changes in adults with chest tumors.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Hebei Medical University Fourth Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Shijiazhuang, Hebei) |
| Status | Recruiting |
| Started | January 17, 2026 |
| Main results expected | January 1, 2027 |
| Study ends | January 1, 2027 |
| Registry record updated | June 25, 2026 |
| Trial ID | NCT07669493 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) receiving thoracic radiotherapy for lung, esophageal, breast, or thymus cancers, with preserved heart function (LVEF ≥ 50%) and no severe heart disease.
✕Probably not a fit
Patients with prior thoracic radiotherapy, significant organ disease, or inability to consent may have limited or no direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study following adults who receive thoracic radiotherapy to monitor potential early heart-related changes. Participants will undergo a series of cardiac safety tests at the end of radiotherapy, then at 1 month and 3 months after treatment, including biomarkers, ECG, echocardiography, immune cells, cytokines, lipids, and lipid metabolism markers. The goal is to see if dose parameters to heart structures relate to early safety outcomes and subclinical changes. No experimental treatment is given; the study simply observes and records data during routine care.
Why it matters
Potential benefit: If successful, the study could help clinicians identify early signals of heart risk after thoracic radiotherapy and guide closer monitoring or preventive strategies.
How similar studies have gone: Similar observational efforts have shown that monitoring cardiac biomarkers and imaging can reveal early changes after thoracic radiotherapy, supporting feasibility of this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients willing to participate the research and sign the informed consent file; Patients aged ≥18 years; KPS≥70; Pathological diagnosis for lung cancer, metastatic lung cancer, esophageal cacner, breast cancer and thymus tumor; Patients received thoracic radiotherapy; No functional heart disease; LVEF≥50% Exclusion Criteria: Patients received thoracic radiotherapy previously; Patients with severe organic and functional disease; Unqualified patients with sufficient reasons; Cannot or no willing to sign the informed consent file
Where it's running
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China Recruiting
Study contacts
- Principal investigator: Wu — Hebei Medical University Fourth Hospital
- Study coordinator: Yajing Wu, MD
- Email: wjzs19881212@163.com
- Phone: +8618531118178
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.